It is possible that other IL-6-like signals that activate the JAK2/STAT3 pathway are mediating some of the suppression in other cancer cells as treatment of cGAMP-unresponsive cancer cells with the JAK2/STAT3 inhibitor WP1066 upregulated type I IFN expression in the tested cancer cells. This evidence concerns the gene JAK2 and cancer.